MGMT and IDH1 are established biomarkers associated with patient outcomes, and recent studies reaffirm that MGMT promoter methylation significantly correlates with improved overall survival (OS) in GBM patients, regardless of treatment. This evidence concerns the gene MGMT and glioblastoma.